Rapid Response to Penpulimab Combined With Anlotinib and Chemotherapy in a Thoracic SMARCA4‐UT Without PD‐L1 Expression: A Case Report and Review of Literature
Yuanhang Wang, Kelei Zhao, Jingjing Zhang, Xiaohan Yuan, Yanting Liu, Jinghang Zhang, Ping Lu, Min Zhang · 2024
Read Rapid Response to Penpulimab Combined With Anlotinib and Chemotherapy in a Thoracic SMARCA4‐UT Without PD‐L1 Expression: A Case Report and Review of Literature by Yuanhang Wang, Kelei Zhao, Jingjing Zhang, Xiaohan Yuan, Yanting Liu, Jinghang Zhang, Ping Lu, Min Zhang (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11625506.txt.
Description
Yuanhang Wang and co-authors report a fast response in a man with a rare, aggressive chest tumor tied to a missing gene called SMARCA4. Their 2024 case report and literature review describe a fifty-five-year-old whose cancer had spread to lymph nodes, the chest lining, and bones. Tests showed the tumor lacked a marker that often predicts benefit from immune drugs.
A first drug pair failed, and scans showed growth after one cycle. The team switched to a three-way mix of chemotherapy, an immune drug called penpulimab, and a vessel-blocking pill. The tumor then shrank quickly. The authors weigh this rescue path for a cancer that still has no standard effective treatment.
Catalog record
| CREATOR | Yuanhang Wang, Kelei Zhao, Jingjing Zhang, Xiaohan Yuan, Yanting Liu, Jinghang Zhang, Ping Lu, Min Zhang |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 16 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |